

# PCA3Plus®

THE NEXT GENERATION MOLECULAR TEST FOR PROSTATE CANCER

*Before the availability of molecular testing, physicians relied on serum PSA (prostate specific antigen) tests to monitor for prostate cancer. Elevated serum PSA levels can indicate the presence of prostate cancer, and can point to the necessity for a prostate biopsy. Sometimes biopsy results are negative, but the serum PSA levels remain high. The PCA3Plus test is a non-invasive method to determine those patients who are candidates for rebiopsy.*



## WHAT IS PCA3?

PCA3 is a gene which was discovered in the 1990's. The gene was found to be over-expressed in prostate cancer cells. Later research showed that urine collected after the performance of a light prostatic massage (called an attentive digital rectal exam, or DRE) contained prostate cells in sufficient number to evaluate a patient's risk for prostate cancer.

## WHY PCA3PLUS?

PCA3Plus is a urine-based test which is specific to prostate cancer cells and is a very accurate predictor for prostate cancer. It has a much higher accuracy for prostate cancer detection than PSA levels alone.

	SPECIFICITY
PCA3Plus	74% <sup>1</sup>
PSA	17% <sup>2</sup>

*PCA3Plus has a far higher specificity than PSA.*

The PCA3Plus test is a quantitative molecular assay with a high accuracy for prostate cancer detection. The assay measures the expression of mRNA from the PCA3 gene. The higher the PCA3Plus value, the higher a patient's risk for prostate cancer.

## WHY DO I NEED A PCA3PLUS TEST?

A PCA3Plus test is usually performed when a patient has previously had a negative prostate biopsy, but their PSA levels remain high or continue to rise. Because the test is highly specific for prostate cancer, PCA3Plus helps your physician determine which patients may require a rebiopsy.

1. Marks L S, et al., Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice, Rev Uro 2008; 10(3): 175-181

2. Groskopf, Jack, PhD, senior research scientist, Gen-Probe Inc., Reprint from Urology Times, July 2006

## HOW AND WHERE WILL THE TEST BE PERFORMED?

PCA3Plus tests prostate cancer cells which have been shed into urine. To ensure that the amount of prostate cells collected are sufficient to perform the test, your physician will perform an attentive digital rectal exam (DRE). After the DRE, a urine sample is collected at your physician's office. It is then sent to Bostwick Laboratories for analysis. Results of the test are delivered to your physician in 48-72 hours.

## ADDITIONAL RESOURCES

American Cancer Society (ACS)  
800.ACS.2345  
www.cancer.org

American Urological Association (AUA)  
www.urologyhealth.org

National Cancer Institute  
Cancer Information Service (CIS)  
800.4.CANCER

The Mayo Clinic  
www.mayoclinic.org

The Urology Channel  
www.urologychannel.com

UroToday.com  
www.urotoday.com

## ABOUT BOSTWICK LABORATORIES

Bostwick Laboratories® is a full-service reference laboratory specializing in uropathology.

Dr. David G. Bostwick and our staff of veteran pathologists are dedicated to the diagnosis, treatment and management of prostate cancer, kidney disease, cancer of the bladder and other urologic conditions.

These internationally-renowned board-certified pathologists use the most technologically advanced testing available to ensure accuracy.

Our quick turnaround on reports affords you and your doctor the time you need to choose the best course of treatment.



**BOSTWICK  
LABORATORIES®**

For Absolute Confidence®

877.865.3262

www.bostwicklaboratories.com

Richmond, Virginia | Orlando, Florida | Tempe, Arizona

Uniondale, New York | Nashville, Tennessee | London, England

© 2009 Bostwick Laboratories, Inc. BLU-PE101-0910